Insmed's Phase 3 PALM-PPF trial of inhaled TPIP in pulmonary fibrosis is recruiting
Insmed Incorporated is recruiting for a Phase 3 study testing inhaled TPIP against placebo in progressive pulmonary fibrosis, with one U.S. site listed.
This week's update covers a single registered study from Insmed Incorporated.
- Insmed Incorporated's Phase 3 trial "PALM-PPF" (NCT07805785) is recruiting participants to test Treprostinil Palmitil Inhalation Powder (TPIP) against placebo in adults with progressive pulmonary fibrosis. The primary objective of this study is to evaluate the effect of 52 weeks of once daily treatment with TPIP compared with placebo on lung function in adults with PPF.1 The study plans to enroll 800 participants (estimated)1 and has an estimated primary completion date of 2030-08-31 (estimated)1. The trial is currently listed with 1 site in 1 country: United States, USA001, DuBois, Pennsylvania, United States (recruiting)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.